Skip to main content
. Author manuscript; available in PMC: 2018 May 14.
Published in final edited form as: Clin Cancer Res. 2017 Dec 20;24(6):1389–1401. doi: 10.1158/1078-0432.CCR-17-1958

Figure 2.

Figure 2

Loss of 5-hmC is correlated with a shorter time to relapse following platinum-based chemotherapy and poor prognosis in patients newly diagnosed with HGSOC. A, Progression-free survival of patients with platinum response data (n = 59) shows a significant decrease in average time to disease relapse for patients with low 5-hmC (<2, n = 30) when compared to patients with high 5-hmC (≥2, n = 29). Patients with high 5-hmC levels experience a significantly longer time to initial disease relapse following platinum-based chemotherapy relative to low 5-hmC patients (**, P < 0.01). B, Kaplan–Meier survival curve of all patients with HGSOC included in the BWH TMA (n = 107). Patients with higher 5-hmC levels (primary tumor score ≥2, n = 54) have a significantly increased overall survival when compared with patients with low 5-hmC levels (primary tumor score <2, n = 53; ***, P < 0.0001).